Sökning: WFRF:(Blomqvist Michael)
> (2020-2023) >
Leukocyte nadir as ...
-
Poikonen-Saksela, PaulaHelsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.
(författare)
Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
Informa UK Limited,2020
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-423818
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423818URI
-
https://doi.org/10.1080/0284186X.2020.1757149DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:143717713URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Retrospective studies have suggested that chemotherapy-induced leukopenia is associated with improved recurrence-free or overall survival. The SBG 2000-1 trial was designed to verify the favorable prognosis associated with chemotherapy-induced leukopenia in early breast cancer. Patients not experiencing chemotherapy-induced leukopenia were randomized into standard dosed or individually escalated chemotherapy doses based on the grade of leukopenia after a first standard dose.Patients and methods: 1452 women in Sweden and Denmark with operable node-positive or high-risk node-negative breast cancer aged 18-60 years were recruited to participate in this trial. Participants received a first FEC cycle at standard doses (600/60/600 mg/m(2)). Patients (n = 1052) with nadir leukopenia grade 0-2 after the first cycle were randomized between either 6 standard FEC or 6 tailored FEC courses with doses of epirubicin and cyclophosphamide escalated during courses 2 and 3 and thereafter aimed at achieving grade 3 leukopenia. Patients with nadir leukopenia grade 3-4 after the first course continued treatment with standard FEC. Results of the randomized comparison has been published previously. The present study focuses on chemotherapy-induced leukopenia as a covariable with outcome in randomized and non-randomized patients. The prognostic value of leukopenia after course 3, was studied in a Cox model adjusted for cumulative doses of epirubicin and cyclophosphamide. The association of chemotherapy-induced leukopenia with prognosis was a preplanned secondary endpoint for this trial.Results: The eight-year distant disease-free survival was 73%, 77%, 78% and 83% for patients with leucocyte nadir grade 0, 1, 2 and 3-4, respectively. Higher degree of leukopenia was highly significantly associated to improved distant disease-free survival (HR 0.84, 95% CI 0.74-0.96, p = .008) and overall survival (HR 0.87 (0.76-0.99, p = .032).Conclusion: This prospective study confirms that chemotherapy-induced leukopenia is a covariable with outcome in primary breast cancer, even after adjustment for chemotherapy doses.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Lindman, HenrikUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)henrlind
(författare)
-
Sverrisdottir, AsgerdurSodersjukhuset, Dept Oncol, Stocholm, Sweden.;Landspitali Univ Hosp, Dept Oncol, Reykjavik, Iceland.
(författare)
-
Edlund, PerGävle Cent Hosp, Dept Oncol, Gävle, Sweden.
(författare)
-
Villman, KennethÖrebro Univ Hosp, Dept Oncol, Örebro, Sweden.
(författare)
-
Nittby, Lena TennvallSkane Univ Hosp, Dept Oncol, Malmö, Sweden.
(författare)
-
Cold, SorenOdense Univ Hosp, Dept Oncol, Odense, Denmark.
(författare)
-
Bechmann, TroelsHosp South West Jutland, Dept Oncol, Esbjerg, Denmark.;Vejle Hosp, Dept Oncol, Vejle, Denmark.
(författare)
-
Stenbygaard, LarsAalborg Univ Hosp, Dept Oncol, Aalborg, Denmark.
(författare)
-
Ejlertsen, BentRigshosp, Dept Oncol, Copenhagen, Denmark.
(författare)
-
Andersson, MichaelRigshosp, Dept Oncol, Copenhagen, Denmark.
(författare)
-
Blomqvist, CarlHelsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.;Örebro Univ Hosp, Dept Oncol, Örebro, Sweden.
(författare)
-
Bergh, JonasKarolinska Institutet
(författare)
-
Ahlgren, JohanGävle Cent Hosp, Dept Oncol, Gävle, Sweden.(Swepub:uu)joahl839
(författare)
-
Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.Experimentell och klinisk onkologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Acta Oncologica: Informa UK Limited59:7, s. 825-8320284-186X1651-226X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Poikonen-Saksela ...
-
Lindman, Henrik
-
Sverrisdottir, A ...
-
Edlund, Per
-
Villman, Kenneth
-
Nittby, Lena Ten ...
-
visa fler...
-
Cold, Soren
-
Bechmann, Troels
-
Stenbygaard, Lar ...
-
Ejlertsen, Bent
-
Andersson, Micha ...
-
Blomqvist, Carl
-
Bergh, Jonas
-
Ahlgren, Johan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Acta Oncologica
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet